New System for Eye Surgery a Winner for Carl Zeiss Meditec in India

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Innovative product designed for growth markets successfully launched
- Carl Zeiss Meditec now the single-source partner for all systems
required for cataract treatment

(JENA, 12 February 2009) Carl Zeiss Meditec successfully launched its
new Visalis 100 system for the surgical treatment of cataracts at the
most important ophthalmic meeting in India, the AIOC (All India
Ophthalmology Congress) - which took place this year in Jaipur from 5
- 8 February. For the first time, the company chose a growth market
for the initial presentation of an innovation.
With this new system, Carl Zeiss Meditec is further expanding its
extensive offering of innovative solutions for eye surgery. At the
same time, Visalis 100 is the first system the medical technology
provider is offering that is specifically tailored to the needs of
doctors in emerging markets. With this new product, the company is
reacting to the continuing high level of demand for eye surgery
systems particularly in Asia, but also in other regions. "The
response from doctors was outstanding. The resulting demand clearly
confirms our strategy to continue focusing our developments on the
requirements of our customers in the various regions of the world,"
emphasizes Dr. Michael Kaschke, President and CEO of Carl Zeiss
Meditec AG.
The new Visalis 100 system enables the surgical removal of the
natural, diseased lens from the eye during cataract surgery
(phaco-emulsification). On the introduction of the system, customers
were particularly impressed by its outstanding ease of use and its
carefully matched performance parameters. The Visalis 100 ideally
rounds off Carl Zeiss Meditec's portfolio of innovative solutions for
eye surgery. It can now offer doctors and hospitals a full line of
products for cataract treatment including diagnostic instruments,
surgical microsopes, a phaco system, intraocular lenses and systems
for follow-up care - all from a single source.
"Particularly in the current phase of the global economy, we are
placing increased emphasis on innovation that is sharply focused on
customer requirements. Visalis 100 is a further example of the
implementation of this goal. We recognized the importance of the
newly industrializing countries for our growth at an early stage.
Therefore, it was a logical step for us to introduce Visalis 100 as
our own system specially tailored to the needs of these markets and
hence make the promise of the ZEISS brand something that people could
more actively experience in these markets," Dr. Michael Kaschke
concluded.

--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN:
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in
Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.